A detailed history of Federated Hermes, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 7,859 shares of VERV stock, worth $38,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,859
Previous 1,151,550 99.32%
Holding current value
$38,116
Previous $5.62 Million 99.32%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.4 - $7.86 $5.03 Million - $8.99 Million
-1,143,691 Reduced 99.32%
7,859 $38,000
Q2 2024

Aug 08, 2024

SELL
$4.76 - $12.79 $11.4 Million - $30.8 Million
-2,405,027 Reduced 67.62%
1,151,550 $5.62 Million
Q1 2024

May 14, 2024

SELL
$10.81 - $17.96 $4.58 Million - $7.61 Million
-423,795 Reduced 10.65%
3,556,577 $47.2 Million
Q4 2023

Jan 31, 2024

BUY
$8.84 - $18.7 $12.8 Million - $27.1 Million
1,448,003 Added 57.18%
3,980,372 $55.5 Million
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $1.48 Million - $2.7 Million
129,729 Added 5.4%
2,532,369 $33.6 Million
Q1 2023

May 08, 2023

BUY
$14.3 - $24.01 $4.64 Million - $7.79 Million
324,351 Added 15.61%
2,402,640 $34.6 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $5.86 Million - $13.4 Million
328,552 Added 18.78%
2,078,289 $40.2 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $10.2 Million - $27 Million
651,900 Added 59.38%
1,749,737 $60.1 Million
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $4.32 Million - $8.98 Million
387,600 Added 54.57%
1,097,837 $16.8 Million
Q1 2022

May 13, 2022

BUY
$20.92 - $39.36 $7.12 Million - $13.4 Million
340,237 Added 91.96%
710,237 $16.2 Million
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $11.8 Million - $22.3 Million
370,000 New
370,000 $22.3 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.